{"entities":{"Q46693":{"pageid":37064,"ns":120,"title":"Item:Q46693","lastrevid":183446,"modified":"2026-08-13T15:27:46Z","type":"item","id":"Q46693","labels":{"mul":{"language":"mul","value":"LD2F.03"},"pt-br":{"language":"pt-br","value":"Transtorno do espectro do valproato fetal"},"en":{"language":"en","value":"Fetal Valproate Spectrum Disorder"}},"descriptions":{"pt-br":{"language":"pt-br","value":"Transtorno do espectro do valproato fetal e a s\u00edndrome do valproato fetal (FVS) descrevem a gama de sinais e sintomas que ocorrem como consequ\u00eancia da exposi\u00e7\u00e3o ao valproato de s\u00f3dio ou \u00e1cido valpr\u00f3ico no \u00fatero. Uma ampla variedade de anomalias f\u00edsicas ocorre com frequ\u00eancia aumentada, incluindo espinha b\u00edfida, anormalidades maiores e menores nos membros, fissura oral, defeitos card\u00edacos, hiposp\u00e1dia e frouxid\u00e3o articular. Um padr\u00e3o caracter\u00edstico de dismorfismo facial est\u00e1 frequentemente presente, especialmente not\u00e1vel na primeira inf\u00e2ncia. Problemas de neurodesenvolvimento, incluindo QI reduzido, linguagem e desenvolvimento motor mais pobres, taxas aumentadas de transtorno do espectro autista e transtorno de d\u00e9ficit de aten\u00e7\u00e3o e hiperatividade s\u00e3o observados em at\u00e9 40% dos expostos. Problemas de vis\u00e3o como miopia e astigmatismo tamb\u00e9m s\u00e3o comuns. Os riscos dependem da dose e o impacto no c\u00e9rebro pode ser observado em doses menores do que as necess\u00e1rias para as altera\u00e7\u00f5es do desenvolvimento f\u00edsico."},"en":{"language":"en","value":"Fetal valproate spectrum disorder (FVSD) and Fetal valproate syndrome (FVS) describe the range of signs and symptoms which occur as a consequence of exposure to sodium valproate or valproic acid in the womb. A wide range of physical anomalies occur at increased frequency, including spina bifida, major and minor limb abnormalities, oral clefting, cardiac defects, hypospadias, and joint laxity. A characteristic pattern of facial dysmorphism is frequently present, especially notable in early childhood. Neurodevelopmental problems including reduced IQ, poorer language and motor development, increased rates of autistic spectrum disorder and attention deficit hyperactivity disorder are observed in up to 40% of those exposed. Vision problems such as myopia and astigmatism are also common. Risks are dose dependent and the impact on the brain may be seen at lower doses than those required for physical development alterations."}},"aliases":{},"claims":{"P68":[{"mainsnak":{"snaktype":"value","property":"P68","hash":"14a56e35acab43528abad70b3a547135fda50a83","datavalue":{"value":"https://id.who.int/icd/entity/1055155432","type":"string"},"datatype":"url"},"type":"statement","id":"Q46693$852B51C3-3B84-4D2C-B092-1A96906F136A","rank":"normal"}],"P67":[{"mainsnak":{"snaktype":"value","property":"P67","hash":"8945affd40ba3122110dcd5b4a9822a5a517c57e","datavalue":{"value":"CID11:LD2F.03","type":"string"},"datatype":"string"},"type":"statement","id":"Q46693$A31FB023-B21E-48B0-89B4-F9EB39A6413E","rank":"normal"}],"P70":[{"mainsnak":{"snaktype":"value","property":"P70","hash":"7cf7c5a455a1dfe082eefddc89483a688c794b02","datavalue":{"value":"dki-india-LD2F.03","type":"string"},"datatype":"string"},"type":"statement","id":"Q46693$A1A9D146-C0F0-4AE3-8D77-33CACE2199B2","rank":"normal"}],"P86":[{"mainsnak":{"snaktype":"value","property":"P86","hash":"a96031634b9f5dafddaf781bbba3adea6bb64ef4","datavalue":{"value":"Conclu\u00eddo","type":"string"},"datatype":"string"},"type":"statement","id":"Q46693$4F4038B9-7924-4465-AFEB-CBA4FA814C31","rank":"normal"}],"P78":[{"mainsnak":{"snaktype":"value","property":"P78","hash":"5f9b5be68b7400da549761cf15abfdbc4d1e075b","datavalue":{"value":"https://pauloleads.com.br/cases-publicos/","type":"string"},"datatype":"url"},"type":"statement","id":"Q46693$28715610-8E16-4780-AF6D-AA6029E80740","rank":"normal"}],"P80":[{"mainsnak":{"snaktype":"value","property":"P80","hash":"92b8222fcbb75718504f915073a3f43bd4003d18","datavalue":{"value":{"time":"+2026-08-13T00:00:00Z","timezone":0,"before":0,"after":0,"precision":11,"calendarmodel":"http://www.wikidata.org/entity/Q1985727"},"type":"time"},"datatype":"time"},"type":"statement","id":"Q46693$B6E7665C-7791-426F-B123-5E1CAECE3EAE","rank":"normal"}],"P89":[{"mainsnak":{"snaktype":"value","property":"P89","hash":"1d4ab87306805a1c1fff790766a5af25593ba674","datavalue":{"value":{"entity-type":"item","numeric-id":22362,"id":"Q22362"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q46693$368FC209-FEE1-49BF-8F9F-8329D43AE2C3","rank":"normal"}]},"sitelinks":{}}}}